Baxter International (BAX)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$22.86+1.22%
Close 2026-07-07 · 1-day change
Reading BAX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BAX free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading BAX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BAX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
BAX represents a turnaround investment with a focus on recovery in its financial performance. The current thesis state remains intact, but the company is navigating through volatility and loss-making conditions.
The valuation of BAX is considered expensive compared to its peers, with a notable expectations gap. The market seems to have priced in a level of fragility, but recent performance has kept it in the top half of its industry.
Management has reiterated its full-year financial outlook, but recent results show limited progress, including a net income loss. The near-term risk of missing earnings is low, but trends in earnings surprises are declining.
The future performance of BAX hinges on guidance during the next earnings call and the performance of sector bellwethers like ISRG, MDLN, and BDX. Positive momentum in the healthcare sector could support BAX, while negative trends could pose risks.
Over the next 1 to 3 years, BAX's performance will depend on its ability to stabilize earnings and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show how the company is doing after selling Kidney Care.
Confirms one read:Earnings results show operational sales growth of 4% or more year over year.
Confirms the other:Earnings results show sales growth under 2% compared to last year.
Why it matters: Earnings results will show if Baxter meets its financial outlook. This is key for investor confidence.
Confirms one read:Q2 2026 adjusted EPS reported above the range of $1.85 to $2.05.
Confirms the other:Q2 2026 adjusted EPS reported below $1.85.
Why it matters: A new CEO can set a fresh direction for Baxter. This could impact growth and strategy.
Confirms:The Board of Directors announced a permanent CEO.
Disproves:Continued interim leadership without a permanent CEO for more than six months.
Why it matters: Advancements in GPS can drive operational improvements and growth. This is key for long-term success.
Confirms:Management reports clear improvements in operations. These are linked to the use of GPS.
Disproves:No progress or metrics show stagnation in GPS projects.
Why it matters: A smooth CFO transition is key for keeping finances stable and gaining investor trust.
Confirms one read:The company names a new CFO with a clear plan for the future.
Confirms the other:The CFO change may cause instability. It could also delay financial reports.
Why it matters: A new CEO could set a fresh direction for Baxter and impact its strategy. Investors will look for stability and vision in leadership.
Confirms:The company will name a permanent CEO before the earnings call on July 30, 2026.
Disproves:No permanent CEO is appointed by the next earnings call, leaving interim leadership in place.
Why it matters: Tariffs may raise costs and hurt margins, affecting Baxter's financial results.
Confirms:The company says tariffs will impact less than expected. They are keeping margin guidance.
Disproves:The company lowers its margin guidance because of tariff effects.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Tariffs could affect costs and margins. Clarity on this will inform financial outlook.
Confirms:Management will give a clear update on tariff effects in the Q2 earnings call.
Disproves:No mention of tariffs or their impact during the Q2 earnings call.